Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My post...
did not achieve the point I was attempting to make...
per my post "#geothermal has of late been more then the usual" I was speaking of twitter. Seems the discussion of geothermal is more active as of late.
I am a fan of HTM...my apologies for the confusion.
tis
HTM...
http://www.sauder.ubc.ca/Faculty/Research_Centres/ISIS/Programs/Clean_Capital/Clean_Capital_News_Archive_2014/Despite_growth_south_of_the_border_Canada_is_tepid_on_geothermal_energy?utm_source=getresponse&utm_medium=email&utm_campaign=cleancapitalnews&utm_content=CC+News+-+Canadian+geothermal+grows+tepid%2C+a+world+without+power+plants%2C+indigenous+mapping+project%2C+and+more
#geothermal has of late been more then the usual
tis
Seems to have been...
quite a few of persons with the power of the pen/keyboard/internet wishing to see this one brought down on the 26th.
tis
"Hooper Holmes is worth at least $2-3 in a buyout"
http://seekingalpha.com/instablog/23424843-the-ice-princess/2784293-this-growth-stock-has-400-percent-upside-potential
Interesting read/opinion...
tis
Ukraine turmoil drives ETP flows into palladium
http://www.fundweb.co.uk/news-and-analysis/alternatives/ukraine-turmoil-drives-etp-flows-into-palladium/2007724.article
tis
Short Interest in North American Palladium Decreases By 19.3% (PAL)
March 12th, 2014
http://www.americanbankingnews.com/2014/03/12/short-interest-in-north-american-palladium-decreases-by-19-3-pal/
tis
Genopietic of France...
Has anyone inquired/posted in regards to the current status of Genopoietic of France?
tis
Three Links...
Only the first actually mentions "OVAX"...the rest speak of a vaccine.
1) CTCA and the mention of OVAX: http://www.cancercenter.com/ovarian-cancer/ovarian-cancer-vaccine/
2) Youtube video tag "CTCA-Ovarian Vaccine" uploaded Feb 23, 2009:
1,138,874 volume...
closure green.
tis
"from the website..."
So avxt is/has been updating their website (re-joined the company in mid 2013)
tis
Article dated August 14,2013:
Interesting read in regards to Immunotherapy...
Page one:
More than 30 clinical trials involving nearly as many immunotherapy agents have reached the phase III stage, according to the Cancer Research Institute, a New York City nonprofit that provides funding to scientists in the field.
Page two:
Becker observed that smaller biotechnology companies, often with market capitalization values below $300 million, historically have been tackling cancer vaccine development. Now, however, pharmaceutical giants are engaging in research, Becker said. In addition, he said, many of the therapies take into account limits of prior agents.
“The era of skepticism over use of the body’s immune system to effectively treat cancer has officially come to an end,” Becker wrote. “We are now firmly in the early stages of the cancer immunotherapy revolution.”
Page three:
A mention/reference to M-VAX
http://www.onclive.com/publications/oncology-live/2013/july-2013/immunotherapy-hits-new-peak-asco-data-stir-excitement-investment/3
tis
Patents...
Assignee: AVXT
http://patents.justia.com/search?q=AVAX+TECHNOLOGIES%2C+INC.
Inventor: David Berd
http://patents.justia.com/search?q=david+berd
tis
News this morning...
Over...
1.1 million in volume today...not an awesome number...still heavier then normal.
1 mill + sitting on the bid @ .023
tis
Could be a sign...
Perhaps the "dark" days are coming to an end...we shall see.
tis
News....
http://finance.yahoo.com/news/avax-technologies-announces-expansion-clinical-151700533.html
Me thinks this may get very interesting...
tis
giddy up...
tis
giddy up...
tis
"Bad ass"
I ask...do any of the 39 "bad ass" photos have her standing over/near four Caskets.
And please note...I do not open "dailykos" links.
Peace to You and Yours...
tis
Nice!
tis
Is getting close...
.65 @ 12:13
tis
public offering of 7,780,000 shares of its common stock, offered at a price to the public of $0.45 per share.
http://boardvote.com/symbol/IDN/communique/525299
tis
From the link you provided:
FDA Study Aimed at Harnessing Immune Systemto Fight Tumors Now Available at All Five Hospital Sites
CHICAGO, Jan. 8, 2014 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America® (CTCA), a leading provider of innovative cancer care for patients living with complex and advanced-stage disease, is now enrolling patients in an ovarian cancer vaccine clinical trial at all five of its hospital sites. CTCA Western Regional Medical Center (WRMC) in suburban Phoenix, Arizona and Southeastern Regional Medical Center (SERMC) in suburban Atlanta, GA are the two newest sites to participate in the Phase I/II study. The study evaluates the safety and the immune stimulating activity of this unique ovarian cancer vaccine therapy in patients with recurrent ovarian cancer.
(Logo: http://photos.prnewswire.com/prnh/20090612/CTCALOGO)
The American Cancer Society ranks ovarian cancer as the ninth most common cancer among women, and it is the fifth leading cause of cancer-related deaths in women. It is estimated that there will be about 22,240 new cases of ovarian cancer in the U.S. in this year, and that more than 14,000 women will die of the disease in 2013. Currently, 1 in 72 women will be diagnosed with ovarian cancer and there is a 1 in 100 chance that, in a woman's lifetime, she will develop the disease.
The study is being conducted at all Cancer Treatment Centers of America hospitals. Eligible participants must have recurrent ovarian cancer. Participants must first undergo surgery at a CTCA hospital to remove the ovarian tumor. Patients become eligible for the vaccine trial when it is determined that enough tumor cells have been harvested from the resected tumor to create the vaccine.
CTCA, in consort with the trial's sponsor Avax Technologies, Inc., will create a personalized vaccine, using each patient's own tumor cells that have been surgically removed. These cells will be chemically-modified in the Avax laboratories by a proprietary process designed to increase the immunologic response to the patient's ovarian cancer.
"This is another example of the emergence of personalized medicine into the field of oncology," noted Maurie Markman, MD, CTCA Senior Vice President, Clinical Affairs and National Director, Medical Oncology. "The potential for vaccine therapy is enormous and we are extremely pleased to be leading this study."
Additional information about the vaccine trial, ovarian cancer, and ovarian cancer treatment can be found at cancercenter.com/ovarian-cancer.
About Cancer Treatment Centers of America
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.
About Avax Technologies, Inc.
Avax Technologies, Inc.specializes in the development and commercialization of a universal cancer immuno-therapeutic, the Autologous Cell "(AC) Vaccine™ Technology. The AC Vaccine™ Platform is a patented, therapeutic approach that stimulates the patient's own immune system to recognize, contain and eliminate cancer using the most relevant tumor antigens, the Patients own tumor cells.
SOURCE Cancer Treatment Centers of America
RELATED LINKS
http://www.cancercenter.com
Encouraging...
tis
Bid...
is starting to build a bit.
tis
There is news today...
concerning Cancer Treatment Centers to which mentions AVAX to which came across my "news" on tda.
I am unable to find/pull it for posting...perhaps someone else can.
tis
giddy up time....
perhaps
tis
an excellent morning...
tis
MSNBC...
Shall see the "flat line" long before Fox fails...
I like this:
"The Kelly File" drew 289,264 viewers age 25-54. It was beaten by Rachel Maddow, who drew 298,543 viewers in the demo."
Total in the age of 25-54: 9279
http://www.huffingtonpost.com/2013/10/08/megyn-kelly-ratings-file-premiere_n_4066130.html
The Kos:
"Rachel Maddow Whomps Megyn Kelly's Premiere On Fox News" (ROFL)
http://www.dailykos.com/story/2013/10/09/1245489/-Rachel-Maddow-Whomps-Megyn-Kelly-s-Premiere-On-Fox-News
Day 2:
Perhaps most dramatically, Kelly's narrow loss to Rachel Maddow from a night earlier was significantly reversed, with Kelly drawing an audience of 623,000 in the key demo compared with Maddow's 291,000.
http://www.hollywoodreporter.com/news/msnbc-president-wants-investigation-fox-647852
‘The Kelly File’ ratings surge is legit: Nielsen
MSNBC questioned its competitor’s 100% ratings increase but the further investigation shows Fox’s Megyn Kelly did crush MSNBC’s Rachel Maddow.
Nielsen has conducted an investigation into the ratings for Megyn Kelly’s new Fox News Channel show, “The Kelly File,” following grousing by MSNBC chief Phil Griffin.
The investigation has revealed that the numbers for Kelly are accurate.
Last Tuesday, the day after its debut, “The Kelly File” doubled its audience, crushing “The Rachel Maddow Show,” its MSNBC competition.
Griffin called for a probe, dubbing the ratings feat “impossible.”
Read more: http://www.nydailynews.com/entertainment/kelly-file-surge-legit-nielsen-article-1.1485556#ixzz2pgEgAf00
Imagine that!!!
tis
You know...
better
As does the rest of the world (logic/common sense).
By the way:
http://www.businessinsider.com/megyn-kelly-ratings-fox-news-msnbc-investigation-nielsen-2013-10
Peace to you and yours...
tis
SA Article...Dec 22, 2013
Rexahn: A Turn Around Story For 2014
http://seekingalpha.com/article/1911591-rexahn-a-turn-around-story-for-2014?source=ansh%20$RNN
tis
Perhaps...
SYN........Giddy up time...
tis
Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash; Transaction Value of $250M
Read more: http://www.benzinga.com/news/13/12/4157334/valeant-pharmaceuticals-agrees-to-acquire-solta-medical-for-2-92-per-share-in-cas#ixzz2ndxLvZcd
tis